Overview

Naloxegol US PMR CV Safety.

Status:
Active, not recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in patients aged 18 years and older who do not have a diagnosis of cancer and who are treated with opioids chronically

Details

Lead Sponsor:

AstraZeneca
RedHill Biopharma, Inc.

Treatments:

Naloxegol